Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Anti-AAV8 Antibody Assessment Study of Males With Duchenne Muscular Dystrophy Aged 0 to <25 Years

NCT05683379 is registered in ClinicalTrials.gov with REGENXBIO Inc. as lead sponsor.

NCT NCT05683379
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05683379 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Anti-AAV8 Antibody Assessment Study of Males With Duchenne Muscular Dystrophy Aged 0 to <25 Years
Lead sponsor
REGENXBIO Inc.
Phase
Observational
Overall status
Active, not recruiting
Start date
December 20, 2022
Completion date
September 30, 2026
Enrollment
200 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

duchenne muscular dystrophy